Oruka Therapeutics shares are trading higher after Wedbush initiated coverage on the stock with an Outperform rating and announced a $40 price target.
Portfolio Pulse from Benzinga Newsdesk
Oruka Therapeutics shares rose after Wedbush initiated coverage with an Outperform rating and a $40 price target.
September 04, 2024 | 5:28 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oruka Therapeutics shares increased following Wedbush's initiation of coverage with an Outperform rating and a $40 price target.
The initiation of coverage by Wedbush with an Outperform rating and a $40 price target is a positive signal to investors, likely leading to increased buying interest and a short-term price increase.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100